Arca
Skip to content
Tools
Tools

NTRK2: BDNF/NT-3 growth factors receptor

Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on NTRK2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Other 1

Approved1

  • Repotrectinib

Phase 31

  • Lestaurtinib

Phase 20

    Phase 12

    • AZD-7451
    • PLX-7486

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Neurotrophic tyrosine kinase receptor type 2 inhibitor.
    RepotrectinibApprovedBristol-Myers SquibbSmall moleculeInhibitor8
    LestaurtinibPhase 3Teva Pharmaceutical IndustriesSmall moleculeInhibitor0
    AZD-7451Phase 1—Small moleculeInhibitor0
    PLX-7486Phase 1PlexxikonOtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in JapanRepotrectinib—RecruitingBristol-Myers SquibbAug 10, 2026
    Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionRepotrectinib—Not yet recruitingBristol-Myers SquibbMay 20, 2026
    Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCRepotrectinibPhase 2RecruitingCentre Hospitalier Intercommunal de Toulon La Seyne sur MerAug 13, 2024
    Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRepotrectinibPhase 2RecruitingMedSIRMar 18, 2024
    A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)RepotrectinibPhase 3Active, not recruitingBristol-Myers SquibbNov 20, 2023
    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRepotrectinibPhase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer CenterAug 13, 2021
    A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.Sep 19, 2019
    A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.Mar 28, 2017

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Obesity, hyperphagia, and developmental delay0.71
    • Non-small cell lung carcinoma0.65
    • Neoplasm0.65
    • Cancer0.65
    • Genetic developmental and epileptic encephalopathy0.61
    • Neurodegenerative disease0.50
    • Hereditary disease0.45
    • Mathematical ability0.41
    • Refractive error0.39
    • Undetermined early-onset epileptic encephalopathy0.38

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4898, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q16620, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.